Somatostatin Receptor Ligands

Specific Drugs in this Class

Indications

Second or third-line therapy to control the metabolic effects of acromegaly, Cushing’s disease, and TSH-producing pituitary adenomas, in patients who did not achieve a biochemical remission after surgery and/or radiation therapy.

Effectiveness

Side Effects

Resistance to SRLs

Approx 10% of GH-producing adenomas are considered “resistant” to treatment with SRLs. Possible predictors of resistance are:

Alternatives

In patients who do not respond to SRLs, consider:

Also consider radiation therapy or repeat surgery, if resectable.

References